Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The ENST00000357654.9(BRCA1):āc.5527G>Cā(p.Ala1843Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,840 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A1843E) has been classified as Likely pathogenic.
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
In a hotspot region, there are 6 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 10 benign, 17 uncertain in ENST00000357654.9
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr17-43045742-G-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 182082.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=1, Uncertain_significance=2, not_provided=1}.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.87
PP5
Variant 17-43045743-C-G is Pathogenic according to our data. Variant chr17-43045743-C-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 55614.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Likely pathogenic, criteria provided, single submitter
clinical testing
Ambry Genetics
Sep 07, 2016
The p.A1843P variant (also known as c.5527G>C), located in coding exon 22 of the BRCA1 gene, results from a G to C substitution at nucleotide position 5527. The alanine at codon 1843 is replaced by proline, an amino acid with highly similar properties. This variant was previously detected in a Japanese female with a personal and family history of ovarian cancer (Sekine M et al Clin Cancer Res. 2001; 7(10):3144-50). Functional studies have demonstrated that this variant, which is located in the BRCT domain, results in a moderately destabilizing protein (Rowling PJ et al. J. Biol. Chem., 2010 Jun;285:20080-7; Lee MS et al. Cancer Res., 2010 Jun;70:4880-90). Based on internal structural analysis, this variant is anticipated to result in a significant decrease in structural stability (Clapperton JA et al. Nat Struct Mol Biol. 2004; 11(6):512-8; Ambry Internal Data). This variant was previously reported in the SNPDatabase as rs80357019, but was absent from population-based cohorts in the NHLBI Exome Sequencing Project (ESP) and 1000 Genomes Project databases. To date, this alteration has been detected with an allele frequency of approximately 0.0003% (greater than 300000 alleles tested) in our clinical cohort. This amino acid position is well conserved in available vertebrate species. In addition, this variant is predicted to be possibly damaging and deleterious by PolyPhen and SIFT, as well as other various in silico tools (Mirkovic N et al. Cancer Res., 2004 Jun;64:3790-7). Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Hereditary breast ovarian cancer syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter
clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Aug 13, 2018
Variant summary: BRCA1 c.5527G>C (p.Ala1843Pro) results in a non-conservative amino acid change located in the BRCT domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 246124 control chromosomes (gnomAD). c.5527G>C has been reported in the literature in an individual affected with Hereditary Breast and Ovarian Cancer (Sekine_2001). This data does not allow any conclusion about variant significance. Several functional studies have found the variant to be moderately destabilizing in multiple measures such as reduced protein stability, significantly decreased transcriptional activity, and homologous recombination (Lee_2010, Rowling_2010, Gaboriau_2015). A ClinVar submission from another clinical diagnostic laboratory (evaluation after 2014) cites the variant as "likely pathogenic." Based on the evidence outlined above, the variant was classified as likely pathogenic. -